| abstract |
The present invention provides a new dosage form of GLP-1 receptor agonists for improving insulin lowering and lower insulin side effects and drug interactions, and an insulin resistance improving agent for such administrations, and provides for continuous action of GLP-1 receptor agonists. Rather, at least before food, or preferably non-invasively, repeated for a period of time, creating a situation in which endogenous GLP-1 receptor agonists are secreted temporarily after each meal, thereby endogenous in healthy individuals. An administration method for obtaining a plasma concentration change that mimics or enhances circadian fluctuations of a GLP-1 receptor agonist and a pharmaceutical composition comprising the GLP-1 receptor agonist for such administration as an active ingredient are provided. |